SUBSCRIBE: Print / eNewsletter
Dual HER2 Blockade Promising in HER2-Positive Metastatic CRC
Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.
Vaccines to Prevent High-Grade Glioma
This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.
Biomarkers Could Predict Bladder Cancer Progression
This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.
Immunotherapeutic Agents in Breast Cancer
This video reviews the latest trials and research on immunotherapeutic agents being tested in breast cancer.
CheckMate 067 Shows OS Improved With Nivolumab/Ipilimumab in Melanoma
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.
MicroRNA Signature Predicted Breast Cancer Survival, Bone Metastasis
This video highlights a novel scoring system using microRNA signatures that predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.
Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma
This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.
Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders
In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.
CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.
Prostate Cancer Death Linked With Shorter Sleep Duration
This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.